# TuHURA Biosciences, Inc./NV

**HURA**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001498382


# None

### No letter

2 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $27.4M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data, degenerate in...<br>not computable: dilution, distress |
| **Inputs computable** | 2 of 14 |
| **Graded from** | filings received through Apr 30, 2026<br>183 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $2.08<br>2026-10-29; market equity $132.6M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 31, 2026*

We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 40.5** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *required facts have no common fiscal period end* | | | | | |
| Accruals ratio | (10.2%) | (6.6%) | 40.5 | 805 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 91.6** | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | not computable | (0.33) | | | |
| *required facts have no common fiscal period end* | | | | | |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *required facts have no common fiscal period end* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *required facts have no common fiscal period end* | | | | | |
| Current ratio | 0.78x | 2.94x | 91.6 | 832 | 2025-12-31 |
| **Growth and financing** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 3* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *four consecutive annual FCF observations are required; found 2* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *required facts have no common fiscal period end* | | | | | |
| Asset growth, three years | not computable | 2.1% | | | |
| *four consecutive annual observations are required* | | | | | |
| Net share issuance, one year | not computable | 2.5% | | | |
| *prior share count is 32 days earlier* | | | | | |

## Warnings

*4 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 0.4 months |
| Thin data | 2 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |
| Fortress balance sheet | cash minus debt is 5,970,878 USD; Altman Z is not used |

## What the price implies

*at the 2026-10-29 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (14.1%) | 7.7% | 36 |
| Distance from 52-week high | (34.6%) | (26.6%) | 40 |
| EBIT to enterprise value | (0.01%) | (1.4%) | 55 |
| Free cash flow yield | (21.1%) | (0.9%) | 23 |
| Book value to price | 0.14 | 0.27 | 34 |
| Sales to price | 0.00 | 0.30 | 0 |
| Composite equity issuance, five years | 785.7% | 20.5% | 99 |
| Relative strength against the sector, log excess return | (0.36) | (0.14) | 36 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $995,977 |
| Operating cash flow, four quarters | -$29.7M |
| Months of runway | 0.4 |
| Days since last periodic filing | 77 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $409,331 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$30.1M | 2025-12-31 | 2026-03-31 | 10-K | 26-134950 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$27.6M | 2025-12-31 | 2026-03-31 | 10-K | 26-134950 |
| 3 | assets | us-gaap:Assets | $27.4M | 2025-12-31 | 2026-03-31 | 10-K | 26-134950 |
| 4 | assets | us-gaap:Assets | $20.0M | 2024-12-31 | 2026-03-31 | 10-K | 26-134950 |
| 5 | current assets | us-gaap:AssetsCurrent | $4.6M | 2025-12-31 | 2026-03-31 | 10-K | 26-134950 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $5.9M | 2025-12-31 | 2026-03-31 | 10-K | 26-134950 |
| 7 | revenue | us-gaap:Revenues | $0 | 2025-12-31 | 2026-03-31 | 10-K | 26-134950 |
| 8 | revenue | us-gaap:Revenues | $0 | 2024-12-31 | 2026-03-31 | 10-K | 26-134950 |
| 9 | revenue | us-gaap:Revenues | $0 | 2012-06-30 | 2012-12-20 | 10-K/A | 12-001331 |
| 10 | assets | us-gaap:Assets | $6.2M | 2024-06-30 | 2024-10-07 | 10-K | 24-113321 |
| 11 | assets | us-gaap:Assets | $4.0M | 2023-06-30 | 2024-10-07 | 10-K | 24-113321 |
| 12 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 63,682,528 | 2026-04-24 | 2026-04-30 | 10-K/A | 26-197486 |
| 13 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 63,578,528 | 2026-03-23 | 2026-03-31 | 10-K | 26-134950 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.